Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Immunome Medical Monitor
CONTACT
Lead
Immunome, Inc.
This is a Phase 1 open-label, multicenter, dose escalation and expansion study designed to determine the safety, tolerability, PK, and preliminary antitumor activity of IM-1340 administered to participants with advanced solid tumors. The study consists of 2 parts: Part A: A dose-escalation phase to evaluate the safety and tolerability of IM-1340 to determine the recommended dose for expansion (RDE) and evaluate maximum tolerated dose (MTD) and/or maximum achievable dose. Part B: An expansion phase to further evaluate the safety and preliminary antitumor activity of IM-1340 monotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted